The C1qScreen assay is a highly sensitive and specific test for detecting complement-binding antibodies. Identify patients who may benefit from more aggressive immunosuppressive therapies by monitoring for C1q-binding donor-specific antibodies (DSAs)

For the C1q Binding assay, refer to ARUP test code 0050301. The C1q Binding assay detects circulating immune complexes. The Complement Component 1q Level assay quantifies the active fraction component, C1q, of the C1 complement protein complex.

The One Lambda ™ C1qScreen assay combines the sensitivity of Luminex ® solid-phase technology with the specificity of anti-HLA single antigen detection for identifying complement-binding

This chapter describes a novel solid phase C1q binding assay to distinguish HLA antibodies that can bind the first component of complement (C1q). These antibodies have the capacity to initiate the complement cascade irrespective of whether that actually occurs.

Circulating immune complexes can be demonstrated in rheumatic, infectious, and neoplastic diseases, as well as most immunologically mediated illnesses (inflammatory bowel disease, thrombotic thrombocytopenic purpura).

Identification of a major linear C1q epitope allows detection of systemic lupus erythematosus anti-C1q antibodies by a specific peptide-based enzyme-linked immunosorbent assay. Arthritis Rheum. 64, 3706–3714 10.1002/art.34605 [ DOI ] [ PubMed ] [ Google Scholar ]

Feb 25, 2021 · Sartorius has developed a specific and sensitive C1q assay using the SPR platform that can be used to assess binding to C1q. The data from this assay can be combined with C1q ELISA and C1q bioassay data to give a more …

C1q Antibody (IgG) - This assay serves as a non-invasive aid for the diagnosis of active proliferative lupus nephritis (LN) and for monitoring disease activity. Autoantibodies to C1q (C1q Ab; IgG isotype) are detected in a number of autoimmune and infectious diseases but are best described in patients with systemic lupus erythematosus (SLE).

C1q recognizes and binds to immunoglobulin complexed to antigen and initiates the complement cascade. Congenital deficiencies of any of the early complement components (C1, C2, C4) results in an inability to clear immune complexes.

Detect circulating immune complexes. Indicates whether a test has been approved by the New York State Department of Health. This test is New York state approved. Patient Preparation Instructions patient must follow before/during specimen collection. Collect Specimen type to collect. May include collection media, tubes, kits, etc.